Sylvia Wheeler has left the VP of IR and corporate communications slot at Hyperion for a similar role at Relypsa, the biopharmaceutical company with a hyperkalemia drug in Phase 3 clinical trials.
Wheeler, as VP of IR and corporate affairs, heads corporate and investor communications reporting to president/CEO John Orwin.
Redwood City, Calif.-based Relypsa went public in a $75M IPO offering in November. The company top drug candidate, patiromer, is a treatment for the potassium blood disorder hyperkalemia.
"Following our initial public offering and strong progress in the development of our lead compound, patiromer, we are pleased to have Sylvia join our team to lead our communications efforts," Orwin said in a statement.
Wheeler previously led corporate comms. at Affymax and held PR posts at Depomed, Cerus Corp. and Coulter Pharmaceuticals.